Amanita muscaria

# Research Output: Amanita muscaria

> **Note on classification**: *Amanita muscaria* is a fungus (Basidiomycete), not a plant. It is treated as a plant-type substance in Psychedex due to its whole-organism preparation and use. Brief seed data fields marked "plant" are functionally correct for pipeline purposes but the generation agent should describe it accurately as a mushroom/fungus throughout.

---

## Botanical Identity

### Accepted Taxonomy

*Amanita muscaria* (L.) Lam. — Family Amanitaceae, Order Agaricales, Class Agaricomycetes, Subphylum Agaricomycotina, Phylum Basidiomycota, Kingdom Fungi [Ref 18].

**Nomenclatural history**: Carl Linnaeus originally described the species as *Agaricus muscarius* in his *Species Plantarum* (1753). Jean-Baptiste Lamarck transferred it to the genus *Amanita* in 1783, yielding the currently accepted binomial *Amanita muscaria* (L.) Lam. [Ref 18].

**Common names**: Fly agaric, fly amanita, mukhomor (Russian).

### Species Complex and Intraspecific Variation

Geml et al. (2006 [Ref 22]) established via ITS and beta-tubulin phylogenies that *A. muscaria sensu lato* encompasses at least three cryptic phylogenetic species (geographic clades): the 'Eurasian', 'Eurasian-alpine', and 'North American' groups. All three were found occurring sympatrically in Alaska, indicating cryptic speciation rather than geographic isolation. The ancestral population is inferred to have evolved in the **Siberian-Beringian region** and subsequently expanded into North America and Eurasia (Geml et al. 2006 [Ref 22]).

A 2026 genomic study by Nickles et al. [Ref 13] sequenced 24 Northern and Southern Hemisphere specimens and confirmed a **European origin** for South African *A. muscaria* (introduced via forestry plantations). The study found 273 molecular families of secondary metabolites, with highly conserved biosynthetic gene clusters across all sampled genomes, suggesting functional conservation of specialized metabolism across continents.

**Recognized varieties** include: *var. muscaria* (red cap, most common), *var. formosa* (yellow/orange cap), *var. alba* (white cap), and *var. guessowii* (yellow-orange, North American). The red-cap form is the most widely recognized and most commonly studied.

### Distribution and Habitat

*A. muscaria* has one of the widest distributions of any fungal species, occurring across Europe, Asia, northern Africa, Australia, New Zealand, and North, Central, and South America (Geml et al. 2006 [Ref 22]). Much of its Southern Hemisphere distribution results from **introduction through forestry** — ectomycorrhizal propagules were introduced alongside non-native timber trees (pine, spruce, birch) planted for commercial forestry (Vargas et al. 2019 [Ref 14]; Nickles et al. 2026 [Ref 13]).

In Colombia, Vargas et al. (2019 [Ref 14]) documented *A. muscaria* spreading from exotic pine and eucalyptus plantations into native *Quercus humboldtii* forests, demonstrating active range expansion as an invasive mutualist.

**Habitat**: Primarily a temperate-to-boreal species, growing in coniferous and mixed deciduous forests. **Obligate ectomycorrhizal fungus** — forms mutualistic associations with tree roots (most commonly birch, pine, spruce, fir, oak). Cannot be cultivated separately from its host trees. Fruiting occurs summer through autumn depending on latitude and elevation.

**Cultivation status**: Wild-harvested only. Not cultivable in isolation from host tree partners. This creates significant batch-to-batch variability in alkaloid content (Michelot & Melendez-Howell 2003 [Ref 1]).

### Morphological Identification

Key features: pileus (cap) 8–20 cm diameter, typically vivid red or orange-red (occasionally yellow to white in variant forms), covered with white to cream-colored universal veil remnants (warts or plaques) that may wash off in rain. Gills free, white, crowded. Stipe white, 5–20 cm tall, with a white to cream skirt-like annulus (ring) and a swollen base enclosed in a white volva [Ref 18].

**Pigmentation**: The red-orange coloration derives from betaxanthin and betacyanin pigments. Stintzing & Schliemann (2007 [Ref 21]) used LC-DAD and mass spectrometry to characterize the complex pigment pattern: betaxanthins (serine, threonine, DOPA, phenylalanine, tryptophan derivatives), betalamic acid, muscaflavin, muscapurpurin, and muscarubrin are present in the cap cuticle.

### Misidentification Risks

**Flag for human review — misidentification is a primary safety concern.**

1. **Amanita pantherina** (panther cap): Brownish-grey cap with white warts; shares the same toxidrome (ibotenic acid/muscimol) but frequently contains **higher alkaloid concentrations** and is considered more dangerous. Commonly misidentified by foragers. Accidental ingestion is the more common clinical scenario in the literature (Benjamin 1992 [Ref 20]; Stoeva-Grigorova et al. 2025 [Ref 2]).

2. **Amanita caesarea** (Caesar's mushroom): Edible; orange cap, yellow gills and stipe. Found in Southern Europe and sometimes confused with *A. muscaria* variants, particularly in Eastern Europe (Brvar et al. 2006 [Ref 10] — patient ate mushrooms presumed to be *A. caesarea*).

3. **Amanita rubescens** (blusher): Edible when cooked; can be confused with *A. pantherina* which shares the toxidrome (Stříbrný et al. 2012 [Ref 12]).

4. **Lethal look-alikes concern**: *Amanita phalloides* (death cap) and *A. ocreata* contain α-amatoxins causing fatal delayed liver failure; not discussed in A. muscaria-specific literature but foragers must distinguish all Amanita species.

---

## Alkaloid / Cannabinoid Profile

*A. muscaria* is not a cannabinoid-containing species. The following are the relevant bioactive compounds.

### Primary Active Constituents

**1. Ibotenic acid**
- PubChem CID: 1233 [Ref verified by database lookup]
- Molecular formula: C₅H₆N₂O₄; MW: 158.11 g/mol
- IUPAC name: 2-amino-2-(3-oxo-1,2-oxazol-5-yl)acetic acid
- InChIKey: IRJCBFDCFXCWGO-UHFFFAOYSA-N
- **Concentration** (fresh): 0.03–0.1% by weight; range documented as low as 0.0025% and as high as 0.18% depending on subspecies and methodology [Ref 26]
- **Concentration** (dried caps): 0.010–2.845 mg/g — extremely high variability [Ref 27]
- **Fresh ratio** IBO:MUS ≈ 9:1 or greater [Ref 25]
- **Mechanism**: Non-selective ionotropic glutamate receptor agonist (NMDA receptor) and metabotropic glutamate receptor agonist; excitatory; neurotoxic at high concentrations (Okhovat et al. 2023 [Ref 5]; Krogsgaard-Larsen & Hansen 1992 per literature [Ref 1])
- Functions as a **prodrug for muscimol** — decarboxylates to muscimol in the GI tract, liver, and brain (Medical Matters 2026 [Ref 27])
- ~10–50% converts to muscimol after decarboxylation in mammalian systems (Nielsen et al. 1985, cited in Medical Matters [Ref 27])

**2. Muscimol**
- PubChem CID: 4266 [Ref verified by database lookup]
- Molecular formula: C₄H₆N₂O₂; MW: 114.10 g/mol
- IUPAC name: 5-(aminomethyl)-1,2-oxazol-3-one
- InChIKey: ZJQHPWUVQPJPQT-UHFFFAOYSA-N
- **Concentration** (dried caps): 0.046–1.203 mg/g [Ref 27]
- **Dried ratio** IBO:MUS ≈ 3:2 [Ref 25]
- **Potency**: At least 5× more active than ibotenic acid (UNODC 1970 [Ref 26])
- **Mechanism**: Selective GABA-A receptor agonist (ionotropic); activates both postsynaptic and extrasynaptic receptors; inhibitory; sedative, anxiolytic, anticonvulsant (Okhovat et al. 2023 [Ref 5])
- The principal psychoactive constituent responsible for the characteristic sedative-hallucinogenic experience

**3. Muscarine**
- PubChem CID: 9308 [Ref verified by database lookup]
- Molecular formula: C₉H₂₀NO₂⁺; MW: 174.26 g/mol
- **Concentration**: 0.0002–0.0003% (calculated as chloride) — extremely low (UNODC 1970 [Ref 26]); approximately 0.0003% dry weight (Medical Matters 2026 [Ref 27])
- **Mechanism**: Muscarinic cholinergic receptor agonist; causes peripheral effects (salivation, lacrimation, nausea)
- **Critical note**: Despite giving its name to muscarinic receptors, muscarine is a **minor constituent** of *A. muscaria* and does NOT account for the central psychoactive effects (UNODC 1970 [Ref 26]; Michelot & Melendez-Howell 2003 [Ref 1]). Atropine therefore has limited utility in management.
- Higher muscarine concentrations found at **lower altitudes**; higher IBO/MUS at higher altitudes [Ref 25]

**4. Muscazone**
- PubChem CID: 92925 [Ref verified by database lookup]
- Molecular formula: C₅H₆N₂O₄; MW: 158.11 g/mol
- IUPAC name: 2-amino-2-(2-oxo-3H-1,3-oxazol-5-yl)acetic acid
- Found **exclusively in European specimens** (UNODC 1970 [Ref 26])
- Neutral amino acid; lower potency than muscimol (Okhovat et al. 2023 [Ref 5])
- Minor contribution to overall toxidrome

### Chemotype / Regional Variation

Alkaloid concentrations in *A. muscaria* are **highly variable** with no reliable predictability. Key sources of variability:
- **Geographic origin**: Three phylogeographic clades with unknown differential chemistry (Geml et al. 2006 [Ref 22])
- **Altitude**: Higher altitude fruiting bodies → more IBO/MUS; lower altitude → more muscarine [Ref 25]
- **Mushroom part**: Caps contain substantially higher concentrations than stems [Ref 27]
- **Collection timing**: Seasonal variation documented (cadmium study by Ordak et al. 2025 cited in [Ref 27])
- **Preparation method**: Major determinant of active compound ratios (see below)

### How Preparation Alters Constituent Ratios

| Preparation | IBO:MUS Ratio | Net Effect |
|---|---|---|
| Fresh, raw | ~9:1 | IBO dominant; excitatory + GI irritation |
| Sun-dried/air-dried | ~3:2 | Partial decarboxylation; MUS increases |
| Hot water infusion (boiled) | MUS dominant | Further decarboxylation; may reduce GI discomfort |
| Ethanol-water extract | Minimal IBO/MUS | Ethanol extraction inefficient for these alkaloids (Dushkov et al. 2023 [Ref 4]) |

*Note*: Dushkov et al. (2023 [Ref 4]) found that a standardized water-ethanol extract and an 80-proof vodka tincture did **not contain significant quantities** of IBO or MUS, suggesting common folk preparation methods may be pharmacologically less potent than expected. The extract demonstrated cytotoxicity attributed to other constituents (ergosterol and other compounds).

**Urine recycling**: Muscimol is excreted substantially unmetabolized in urine (INCHEM [Ref 24]). Historically, Siberian shamans and their communities would drink the urine of those who had consumed the mushroom to re-experience the effects — the urine would contain muscimol while having undergone partial metabolism of ibotenic acid, thereby providing a less toxic route [Ref 25, Ref 28].

---

## History & Ethnobotany

**Flag: The majority of ethnomycological content in this section is sourced from ethnographic and historical literature without modern clinical corroboration. All traditional use claims must be framed as historical and cultural fact, not endorsement.**

### First Scientific Description

Formally described by **Carl Linnaeus** as *Agaricus muscarius* in *Species Plantarum* (1753). Transferred to the genus *Amanita* by **Jean-Baptiste Lamarck** in 1783, yielding the currently accepted binomial (Geml et al. 2006 [Ref 22]).

### Traditional and Indigenous Use

*A. muscaria* has one of the longest documented histories of psychoactive use of any substance. Archaeological and linguistic evidence suggests use spanning thousands of years:

- **Linguistic evidence**: North Asian language analyses dated to ~4000 BCE suggest ancient Siberian use [Ref 25]
- **Archaeological evidence**: Paleolithic Saharan rock paintings may depict mushroom figures [Ref 25]

**Siberian shamanic use** is the best-documented traditional application. Multiple indigenous Siberian peoples used *A. muscaria* in shamanic and ritual contexts, including: the Ostyak, Vogul, Kamchadal, Koryak, and Chukchi [Ref 25; Nyberg 1992 [Ref 28]]. Uses included: ritual intoxication, shamanic trance, divination, and medicinal purposes. The mushroom was reportedly consumed dried or in liquid infusion. The urine-recycling practice (drinking the urine of those who had consumed the mushroom) is documented ethnographically — the rationale is that muscimol passes through unmetabolized while some ibotenic acid is metabolized, producing a more selective and less toxic preparation [Ref 24, Ref 25].

**North American indigenous use**: The Ojibwa and other groups reportedly used *A. muscaria* ceremonially [Ref 25].

**Note on the "soma" hypothesis**: R.G. Wasson (1968 [Ref 30]) proposed in *Soma: Divine Mushroom of Immortality* that *A. muscaria* was the identity of the Vedic soma referenced in the Rigveda. This hypothesis is widely discussed in ethnomycological and psychedelic studies literature (Winkelman 2019 [Ref from OpenAlex]; Shah 2015 [Ref from OpenAlex]) but remains **highly contested and unverified** by most scholars in Vedic studies. The soma question remains open (Gerety 2025 [Ref from OpenAlex]). Flag for editorial judgment on coverage depth.

### Western Discovery and Scientific History

- First formal description: Linnaeus 1753
- First chemical characterization of active compounds: Ibotenic acid isolated in 1960s; muscimol identified subsequently (Michelot & Melendez-Howell 2003 [Ref 1])
- **König-Bersin et al. (1970 [Ref 31])** published early neurochemistry data on monoamine effects under muscimol/IBO influence
- UNODC Bulletin (1970 [Ref 26]) summarized early chemistry understanding
- Michelot & Melendez-Howell (2003 [Ref 1]) produced the most comprehensive integrated review (255 citations in OpenAlex)
- Li & Oberlies (2005 [Ref 9]) catalogued all Amanita genus natural products

### Contemporary Regulatory and Market History

- Louisiana Act No. 159 (effective August 8, 2005): first US state to explicitly restrict A. muscaria intended for human consumption [Ref 32]
- Netherlands ban: end of 2008 [Ref 32]
- Romania ban: 2010 (per ICEERS [Ref 25])
- Google searches for A. muscaria increased 114% from 2022 to 2023, exceeding expected seasonal trends by 97.4% [Ref 29]
- Commercial market emerged in ~2022–2023 in US, featuring gummies, vapes, and pre-rolls containing muscimol
- FDA Scientific Memorandum on A. muscaria: September 2024
- FDA formal letter prohibiting in conventional foods: December 2024 [Ref 17]
- First UK hospitalization from commercial product (microdosing regimen): July 2023 [Ref 17]
- 2025 thematic analysis (Hartwig et al. [Ref 3]): first academic study of community user experiences

---

## Neuroscience & Mechanism

### Primary Receptor Targets

**Muscimol** (primary psychoactive):
- **GABA-A receptor agonist**: Selective agonist at ionotropic GABA-A receptors; binds the GABA recognition site; activates both synaptic and extrasynaptic receptor populations (Okhovat et al. 2023 [Ref 5])
- Activates δ-subunit containing extrasynaptic GABA-A receptors (α4β3δ) with particularly high efficacy — these are tonic inhibition receptors (Adkins et al. 2001 referenced in GABA receptor literature)
- Results in **chloride channel opening**, hyperpolarization, and neuronal inhibition across CNS
- Downstream effects: increased serotonin, decreased catecholamine levels (Medical Matters 2026 [Ref 27]; König-Bersin et al. 1970 [Ref 31])
- Muscimol analogs (THIP/gaboxadol) have been studied in clinical trials for insomnia and pain — mechanistically relevant to muscimol's sleep-promoting and analgesic properties (Okhovat et al. 2023 [Ref 5])

**Ibotenic acid** (excitatory, neurotoxic precursor):
- **NMDA receptor agonist**: Non-selective ionotropic glutamate receptor agonist with excitatory effects (Krogsgaard-Larsen & Hansen 1992 via INCHEM [Ref 24])
- Also activates metabotropic glutamate receptors (mGluR)
- **Excitotoxic** at high concentrations: used experimentally to produce brain lesions; can cause seizures at high doses
- Partially converted to muscimol in vivo — functions as prodrug [Ref 27]
- The biphasic experience (initial stimulation → subsequent sedation) reflects the temporal interplay between ibotenic acid excitation and progressive muscimol dominance as decarboxylation proceeds

**Muscarine** (minor peripheral role):
- Muscarinic cholinergic receptor agonist
- Responsible for cholinergic peripheral signs: salivation, sweating
- Contributes minimally to central effects due to extremely low concentration [Ref 26]

### CNS Effect Summary

The net CNS effect is determined by the ratio of ibotenic acid (excitatory) to muscimol (inhibitory) at time of action. Fresh mushroom preparations provide more ibotenic acid → more initial excitation. Dried/processed preparations provide more muscimol → more sedation and hallucinogenic effects. The biphasic experience reported in ethnomycological accounts and user communities reflects this pharmacodynamic duality (ICEERS [Ref 25]).

### Pharmacokinetics

**No published formal human pharmacokinetic studies found.** The following data are from clinical observations, animal studies, and case reports.

| Parameter | Value | Source |
|---|---|---|
| Onset (oral) | 30–90 min | INCHEM [Ref 24] |
| Peak effects | 2–3 hours | INCHEM [Ref 24] |
| Duration | ~6 hours; residual 10–24 hours | INCHEM [Ref 24] |
| BBB penetration | Yes — active transport | INCHEM [Ref 24] |
| Urinary excretion | Substantially unmetabolized; peak at 2 hours | INCHEM [Ref 24]; Stříbrný et al. 2012 [Ref 12] |
| Detection window (urine) | Within 20–90 min of ingestion | INCHEM [Ref 24] |
| Ibotenic acid conversion | ~10–50% converts to muscimol in GI tract | Medical Matters [Ref 27] |

**GC/MS urinary detection**: Stříbrný et al. (2012 [Ref 12]) developed and validated a GC/MS method for IBO and MUS in urine, demonstrating rapid absorption and excretion. Both compounds are rapidly absorbed from the GI tract and excreted in urine substantially unmetabolized — this explains the traditional urine-drinking practice.

**CYP enzyme involvement**: No published data found on CYP enzyme metabolism of muscimol or ibotenic acid. Both appear to be minimally hepatically metabolized. This is a documented gap.

---

## Effects & Dose by Preparation

**Flag: No controlled human dose-finding studies exist for Amanita muscaria. All dose ranges below are derived from clinical case reports, community reports, and secondary web sources (ICEERS, Medical Matters). These must not be presented as established clinical data.**

### Dose by Preparation

**Oral — dried mushroom cap (whole)**

| Level | Muscimol equivalent | Dried mushroom weight |
|---|---|---|
| Microdose | 0.5–1.5 mg | 0.4–1 g |
| Threshold | ~6 mg | ~5 g |
| Recreational/common | 10–15 mg | 8–10 g |

Source: ICEERS [Ref 25]; Medical Matters [Ref 27]. FLAG — not confirmed by clinical trial.

**Oral — fresh mushroom**

| Level | Fresh weight |
|---|---|
| Threshold | 50–70 g |
| Recreational | 80–100 g |

Source: Medical Matters [Ref 27]. FLAG — high variability due to IBO:MUS ratio in fresh material; not recommended without processing.

**Oral — ibotenic acid (isolated/reference)**

| Level | Ibotenic acid dose |
|---|---|
| Threshold (CNS disturbance) | 30–60 mg (range 30–600 mg per literature) |
| Observable effects (volunteers) | 50–90 mg within 1 hour |

Source: INCHEM [Ref 24].

**Smoked — dried cuticle (cap skin)**
- Anecdotal; faster onset and shorter duration than oral, lower intensity
- No published dose data. Community reports only (Hartwig et al. 2025 [Ref 3]; ICEERS [Ref 25])
- FLAG: No quantitative dose data available

**Oral — hot water infusion/tea**
- No published dose data
- Community reports suggest reduced GI discomfort vs. raw consumption
- Likely produces higher MUS:IBO ratio than raw dried mushroom due to additional heat decarboxylation
- FLAG: Preparation-specific pharmacokinetics unpublished

**Oral — tincture/ethanol extract**
- Dushkov et al. (2023 [Ref 4]) found that ethanol-based extracts (vodka tincture; standardized ethanol-water) do **not contain significant quantities** of IBO or MUS
- Community use of tinctures is common (Hartwig et al. 2025 [Ref 3]) but may reflect placebo or other constituent effects
- FLAG: Safety and potency of commercial tinctures unconfirmed

### Onset and Duration

**Oral (dried mushroom)**:
- Onset: 30–90 min (INCHEM [Ref 24])
- Maximum effects: 2–3 hours (ICEERS [Ref 25]; INCHEM [Ref 24])
- Duration of primary effects: ~6 hours (ICEERS [Ref 25])
- Residual effects: 10–24 hours; next-day hangover documented (INCHEM [Ref 24])

**Smoked**: Faster onset; shorter duration. No published data.

### Subjective Effects Characterization

From case reports (Satora et al. 2005 [Ref 11]; Brvar et al. 2006 [Ref 10]; Rampolli et al. 2021 [Ref 6]) and community thematic analysis (Hartwig et al. 2025 [Ref 3]):

**Multi-phase pattern** (ICEERS [Ref 25]):
1. **Stimulation phase**: Increased energy, mild euphoria (IBO excitatory dominant)
2. **Transition/sedation phase**: Tranquility, drowsiness, ataxia
3. **Hallucinogenic phase**: Visual distortions (size alteration — macropsia/micropsia), auditory disturbances, dreamlike states, mystical awareness

**Commonly reported positive effects** (Hartwig et al. 2025 [Ref 3], community analysis):
- Sedation, relaxation
- Perceptual distortions (visual, auditory)
- Euphoria, well-being
- Dreamlike or oneiric quality
- Enhanced introspection

**Commonly reported adverse effects** (same source):
- Nausea, vomiting
- Dizziness, ataxia
- Confusion, disorientation
- Anxiety, fear
- Next-day fatigue

**Effect modifiers**: Chemotype (var. muscaria vs. formosa), altitude of collection, preparation method, starting IBO content, individual body weight/sensitivity, concurrent GABAergic substance use.

---

## Safety & Toxicity

### LD50 Data

| Compound | Route | Species | LD50 |
|---|---|---|---|
| Muscimol | Oral | Mouse | 22 mg/kg |
| Muscimol | Oral | Rat | 45 mg/kg |
| Muscimol | IV | Rat | 4.5 mg/kg |
| Ibotenic acid | Oral | Mouse | 38 mg/kg |
| Ibotenic acid | Oral | Rat | ~129 mg/kg |

Source: INCHEM [Ref 24]; AJPM [Ref 29]. Context: the AJPM article (2024 [Ref 29]) notes that the acute oral LD50s of muscimol and ibotenic acid in mouse models are **lower** (more toxic) than those of fentanyl, cocaine, and phencyclidine. However, fatal human poisonings remain extremely rare, suggesting the therapeutic window in practice is meaningful.

### Clinical Toxidrome ("Pantherina-Muscaria Syndrome")

The toxidrome is well-characterized and distinct from amatoxin (liver failure) and muscarine-dominant syndromes. From Stoeva-Grigorova et al. (2025 [Ref 2]), Michelot & Melendez-Howell (2003 [Ref 1]), Benjamin (1992 [Ref 20]):

**Onset**: 30–90 min (range 30–180 min in children per Benjamin 1992 [Ref 20])

**Symptoms** (mild-moderate):
- CNS depression, somnolence, confusion, ataxia
- Visual and auditory hallucinations
- Euphoria alternating with dysphoria
- Muscle jerks, fasciculation, spasms
- Nausea, occasional vomiting
- Sweating, salivation

**Symptoms** (severe):
- Coma (documented — Rampolli et al. 2021 [Ref 6]; Stoeva-Grigorova et al. 2025 [Ref 2])
- Seizures/myoclonic twitching (4/9 pediatric cases in Benjamin 1992 [Ref 20])
- Acute respiratory failure (most dangerous per Medical Matters [Ref 27])
- Delirium, psychosis

**Critical note**: Despite muscarine content, the syndrome does **not** present as classic anticholinergic toxidrome. Benjamin (1992 [Ref 20]) specifically documented "no anticholinergic or cholinergic signs were prominent" in pediatric cases. Atropine use is **not recommended** for A. muscaria poisoning (INCHEM [Ref 24]).

### Case Report Evidence

- **Stoeva-Grigorova et al. 2025 [Ref 2]**: Two elderly patients with rapid-onset GI symptoms, CNS depression, cholinergic features; required atropine (authors note this was symptomatic, not specific antidote); full recovery.
- **Brvar et al. 2006 [Ref 10]**: Prolonged **5-day paranoid psychosis** developing 18 hours after ingestion — documents delayed-onset psychiatric complications and extended recovery timeline. Most poisonings resolve within 24 hours; this is an outlier case.
- **Satora et al. 2005 [Ref 11]**: Five young people (18-21) ate dried mushroom at a party for recreational purposes; 4 had visual/auditory hallucinations; 1 lost consciousness; all recovered within 4 days without organ complications.
- **Rampolli et al. 2021 [Ref 6]**: Coma after accidental ingestion (mistaken for edible species); discharged day 4 after rapid mushroom identification.
- **Benjamin 1992 [Ref 20]**: Nine pediatric poisonings (mostly *A. pantherina*); seizures in 4/9; complete recovery; pediatric population appears more susceptible to seizures.

### Psychological Risks

- Prolonged psychosis: documented in at least one case (5 days; Brvar et al. 2006 [Ref 10])
- Anxiety, paranoia: commonly reported adverse effect (Hartwig et al. 2025 [Ref 3])
- Disorientation, confusion: common at higher doses
- Possible precipitated psychiatric episodes in vulnerable individuals: theoretical concern, no published case series

### Mortality

- Fatal human poisonings specifically from *A. muscaria* are **exceedingly rare** (INCHEM [Ref 24]: "death from these mushrooms is extremely rare")
- One fatality documented in a 44-year-old man who ingested four dried caps (cited in AJPM [Ref 29])
- Medical Matters (2026 [Ref 27]) cites a "2–5% fatality rate" from accidental poisoning — **FLAG**: This figure is not confirmed by systematic review; may reflect combined Amanita data including amatoxin species. Treat with low confidence.
- Moss & Hendrickson (2019 [Ref 7]) reviewed poison control data 2002–2016 in North America; relatively few A. muscaria/pantherina cases; outcome data consistent with good prognosis.

### Neurotoxicity of Ibotenic Acid

Ibotenic acid is an established excitotoxin used experimentally to produce focal brain lesions in animal models (NMDA receptor-mediated). Chronic or high-dose exposure raises theoretical concern for hippocampal and other neuronal damage (Medical Matters [Ref 27]). No published human cases of chronic ibotenic acid-induced neurotoxicity have been identified in this literature review. However, this risk may be relevant for commercial preparations with unverified and potentially high IBO content.

### Herb–Drug Interactions

**GABAergic CNS depressants** (HIGH priority — mechanism-established):
- Benzodiazepines, barbiturates, alcohol, other GABA-A agonists: **additive CNS and respiratory depression** expected via shared mechanism (GABA-A agonism). This interaction has a clear mechanistic basis but no published clinical case series. Caution strongly warranted (Medical Matters [Ref 27]; INCHEM [Ref 24]).
- FLAG: No clinical case reports of this specific interaction quantified. Severity classified as mechanistic/theoretical.

**Anticholinergic drugs**: Theoretically attenuate peripheral muscarine effects; clinical relevance minimal given low muscarine content.

**Seizure-threshold-lowering drugs**: Ibotenic acid-mediated excitation may compound risk. No published cases found.

**No published data found on CYP enzyme interactions** for muscimol or ibotenic acid.

### Tolerance and Dependence

**No published clinical data on tolerance development, dependence liability, or withdrawal characterization specific to muscimol or A. muscaria were found in this literature review.** This is a significant data gap.

- Community reports suggest A. muscaria is not compulsively used and has a non-addictive profile (Medical Matters [Ref 27]; Hartwig et al. 2025 [Ref 3])
- Muscimol's GABAergic mechanism is mechanistically analogous to benzodiazepines, which do produce tolerance, dependence, and withdrawal — raising theoretical concern for chronic use
- "Microdosing" guidance from commercial vendors states users "can simply discontinue without unwanted effects" — this lacks rigorous clinical support
- FLAG: Tolerance and dependence data entirely absent from published literature. Generation agent should clearly note this gap.

### Contaminant and Adulterant Risk

**Heavy metals** (significant concern):
- Ordak et al. (2025, cited in Medical Matters [Ref 27]) found **cadmium levels in all A. muscaria supplement preparations significantly exceeded permissible dietary supplement safety limits**, by 4–9× depending on harvest month. Lead concentrations approached threshold values.
- *A. muscaria* naturally bioaccumulates vanadium (as amavadin compound) and other heavy metals from soil; this risk is amplified by collection from contaminated environments.
- The study concluded: "none of the preparations assessed can be considered entirely safe" for frequent consumption.

**Commercial product labeling accuracy**:
- No standardized testing or dosing for commercial A. muscaria gummies/extracts (AJPM 2024 [Ref 29])
- Advertised products claim "500 mg each" per gummy with no accepted potency verification
- No GRAS or NDI notifications filed with FDA for muscimol as food ingredient [Ref 17]

**Misidentification of source material**: Commercial wild-harvested preparations cannot guarantee species identity without professional mycological verification.

### Vulnerable Populations

- **Pediatric**: More susceptible to seizures (Benjamin 1992 [Ref 20]); contraindicated
- **Elderly**: Two severe cases documented in elderly patients (Stoeva-Grigorova et al. 2025 [Ref 2]); increased vulnerability likely
- **Pregnancy**: No data; theoretical concern given GABAergic mechanisms during fetal CNS development; contraindicated
- **Epilepsy/seizure disorders**: IBO excitotoxicity risk; avoid
- **Psychiatric disorders**: Prolonged psychosis documented; use may precipitate or worsen psychiatric episodes
- **Hepatic/renal impairment**: No specific published data

---

## Harm Reduction

- Avoid fresh/raw consumption — IBO is dominant and produces more adverse effects with less predictable psychoactive character
- Drying, then hot water infusion reduces IBO content and may improve tolerability
- Never consume without confident identification (professional mycologist or expert verification)
- Start with very low doses given extreme batch-to-batch variability
- Do not combine with alcohol, benzodiazepines, barbiturates, or other CNS depressants
- Avoid commercial preparations without heavy metal testing documentation
- Children and elderly should not consume
- In overdose: Do NOT induce vomiting (seizure risk); call poison control; activated charcoal within 1 hour if possible; supportive care; benzodiazepines for seizure control (INCHEM [Ref 24])
- No antidote exists; atropine not recommended for central effects [Ref 24]
- Poison Control (US): 1-800-222-1222

---

## Legal Status

### United States

**Federal**: *Amanita muscaria*, muscimol, and ibotenic acid are **NOT listed** on the DEA Controlled Substances Act. Possession and cultivation are federally legal. [Ref 17, Ref 32]

**FDA action**: December 2024 — FDA issued formal letter to industry stating A. muscaria and its specified constituents are **prohibited in conventional food products** as they render products adulterated under the Federal Food, Drug, and Cosmetic Act. No GRAS or NDI notifications have been accepted for muscimol. [Ref 17]

**State-level**: **Louisiana** (Act No. 159, effective August 8, 2005) expressly bans A. muscaria for human consumption; possession, planting, cultivation, growing, or harvesting for aesthetic, landscaping, or decorative purposes is explicitly excluded from the ban. Louisiana is the **only US state** with a confirmed explicit ban. [Ref 32]

### International

| Jurisdiction | Status | Notes |
|---|---|---|
| **Netherlands** | Illegal | Banned since end of 2008; >5g fresh or >0.5g dried = criminal charges [Ref 32] |
| **Australia** | Illegal | Schedule 9 Poisons Standard (prohibited except for approved research) [Ref 32] |
| **Romania** | Illegal | Banned 2010 [Ref 25] |
| **UK** | Legal | Not a controlled substance; possession lawful; marketing for psychoactive effects may invoke Psychoactive Substances Act 2016 [Ref 32] |
| **Germany** | Legal | Not classified as narcotic; applies to most EU member states [Ref 27] |
| **Canada** | Legal | Not scheduled |
| **Russia, Sweden, Ukraine, Thailand, Brazil** | Restrictions reported | FLAG: specific legislation not verified in this review; low confidence [Ref 17] |

**FLAG**: ICEERS [Ref 25] states UK possession, purchase, and sale are prohibited — this **conflicts** with other UK-specific legal sources consulted [Ref 32] which confirm it is not controlled. Requires human review. The UK Psychoactive Substances Act 2016 theoretically applies to marketed products but the mushroom itself is not explicitly scheduled.

### International Treaties

Muscimol and ibotenic acid are **not listed** in the 1961 UN Single Convention on Narcotic Drugs, the 1971 UN Convention on Psychotropic Substances, or the 1988 UN Convention Against Illicit Traffic. The mushroom itself has no UN treaty coverage. The WHO has not conducted a formal critical review of muscimol for scheduling purposes.

---

## Clinical Trials

**No clinical trials** for *Amanita muscaria* or muscimol (derived from this mushroom) were found on ClinicalTrials.gov. Muscimol analogs (notably THIP/gaboxadol) have been studied in registered clinical trials for insomnia and pain — these are synthetic derivatives, not the natural product. This is a confirmed gap; Hartwig et al. (2025 [Ref 3]) explicitly note that "no clinical studies exist thus far" for A. muscaria.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Critical Gaps

1. **All dose values unverified by published clinical trials** — Every dose figure in the effects/dose section derives from web sources (ICEERS, Medical Matters) or community reports. No controlled human dose-finding study exists for any A. muscaria preparation. FLAG for human review on all dose ranges before publishing.

2. **No human pharmacokinetic studies** — Tmax, Cmax, AUC, half-life, and bioavailability data do not exist in published form. All PK data extrapolated from clinical case observations and animal models.

3. **No published tolerance/dependence data** — Muscimol's GABAergic mechanism theoretically parallels benzodiazepine pharmacology; chronic use risks (tolerance, dependence, withdrawal) cannot be excluded but are unstudied. Do not present as "non-addictive" without caveat.

4. **No CYP enzyme data** — No published literature found on hepatic metabolism of muscimol or ibotenic acid via CYP enzymes. Herb–drug interaction severity for CYP-mediated interactions cannot be assessed.

5. **Heavy metals contamination data** — Ordak et al. (2025) cadmium data cited only via Medical Matters review; original publication not directly verified via PubMed. Requires primary source verification.

6. **"2–5% fatality rate"** — Figure cited in Medical Matters [Ref 27]; not confirmed by systematic mortality analysis. May conflate A. muscaria with more toxic Amanita species. Low confidence; flag for editorial scrutiny.

### Legal Status Flags

7. **UK legal status discrepancy**: ICEERS claims possession/purchase prohibited; other UK legal sources confirm it is not controlled. Requires authoritative legal confirmation before publishing.

8. **Russia, Sweden, Ukraine, Thailand, Brazil** restriction claims not verified with specific legislation — low confidence; flag for jurisdictional review.

### Evidence Quality Flags

9. **Traditional use sections** rely entirely on ethnomycological/ethnographic literature (Nyberg 1992 [Ref 28], ICEERS [Ref 25]) without clinical corroboration. All traditional use content must be framed explicitly as historical/cultural documentation, not evidence of therapeutic efficacy.

10. **Dose data from smoked preparation** — purely anecdotal (community reports); no analytical data on alkaloid delivery. Cannot be quantified.

11. **Wasson soma hypothesis** — historically influential but scientifically unverified and contested. Generation agent should present as scholarly hypothesis, not established fact.

12. **Ethanol tincture preparations** — Dushkov et al. 2023 [Ref 4] found essentially no IBO/MUS in ethanol-water extracts. Community use of tinctures (documented in Hartwig et al. [Ref 3]) may produce minimal pharmacological effect from active alkaloids. This finding is important for harm reduction but contradicts lay user expectations.

13. **Emerging commercial product safety** — Commercial muscimol gummies represent a novel delivery form (approximately 2022 onwards) with no published controlled safety data, no standardized dosing, and documented heavy metal contamination risks.

14. **No microdosing data** — Microdosing *A. muscaria* is described in the community (Hartwig et al. 2025 [Ref 3]) and mentioned in the first UK hospitalization, but "remains largely unexplored scientifically" (Medical Matters [Ref 27]).